Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4196 trials
Conditions Major Depressive Disorder, Treatment Res...
Phase PHASE3
Enrollment 418
Locations 12 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

Over 28 million people suffer from current depressive disorder in the European Union. Major depressive disorder (MDD) is one of the most common psychiatric illnesses. The symptoms cause clinically significant distress or impairment in social, occupational, and other important areas of functioning. To treat MDD, there are several antidepressants available and prescribing medication is a process of trial-and-error. Guidelines do not explicitly advise on the order in which antidepressant medication should be prescribed. The choice of antidepressant should be tailored to the patient, while involving the patient in the decision-making process. In general, the choice for the first- and second-line treatment will be a second-generation antidepressant. Recently, esketamine nasal spray (intranasal (IN) administration) was approved for patients with treatment-resistant MDD (TRD). A patient is diagnosed with TRD when having used two antidepressants in sufficient duration and adequate dose without sufficient effect. TRD is associated with a negative impact on quality of life, higher risk for hospitalisations and suicide, comorbidities, poorer social and occupational functioning and a high carer burden. The efficacy of intranasal use of esketamine has been demonstrated in MDD subjects with treatment-resistant symptoms but also in subjects with non-treatment resistant depression, and is approved by the FDA and EMA as a third-line treatment. Besides the registered esketamine nasal spray, which is not available in all countries to all patients because of the high costs, off-label utilization of (es)ketamine infusions (IV) is growing extensively over time to treat TRD. Research conducted so far indicates an unequivocal initial substantial response to (es)ketamine IV in MDD populations, regardless of whether or not patients suffer from treatment resistant MDD. However, until now, there has not been a study investigating this in a sufficiently large population. This may be a unique opportunity to potentially prevent patients progressing into a treatment resistant illness stage. The potential implications of the results of the current study are the prevention of unnecessary trials of ineffective treatments, reducing subject burden substantially, as well as a reduction of healthcare and societal costs.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Drug: Esketamine Nasal Product — See arm description
  • Drug: Ketamine Hydrochloride — See arm description
  • Drug: Esketamine hydrochloride — See arm description
  • Drug: Second-line Antidepressants — See arm description

Primary Outcomes

  • Comparing the change in symptom severity on Montgomery Asberg Depression Rating Scale (6 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2024-08-31
Completion: 2028-06-30
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 418 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Dr. Inge Winter
Collaborators: Universität Münster
Contact Information
Study Contact:
Inge Winter, Dr.
+31875553227
i.winter@umcutrecht.nl
Cynthia Okhuijsen-Pfeifer, Dr.
+31875553227
c.pfeifer@umcutrecht.nl
Alex Hofer, MD, PhD
a.hofer@i-med.ac.at
Medical University Innsbruck
Interventions
  • Drug: Esketamine Nasal Product — See arm description
  • Drug: Ketamine Hydrochloride — See arm description
  • Drug: Esketamine hydrochloride — See arm description
  • Drug: Second-line Antidepressants — See arm description
Study Locations (12 sites)
Medical University Innsbruck, Innsbruck, Austria
Universitätsklinik für Psychiatrie und Psychotherapie Bielefeld, Bielefeld, Germany
LWL-Klinik Dortmund, Bereich Forschung & Wissenschaft, Dortmund, 44287 Germany
University Hospital Frankfurt am Main - Goethe University, Frankfurt am Main, Germany
Westfälische Wilhelms-Universität Münster, Münster, Germany
Eginition Hospital, department of psychiatry, Athens, 11528 Greece
Universita degli Studi di Brescia, Brescia, Italy
University of Cagliari, Cagliari, Italy
Università degli studi della Campania Luigi Vanvitelli, Naples, 80138 Italy
Azienda Ospedaliero-Universitaria "Città della Salute e della Scienza di Torino", Turin, Italy
Eligibility Criteria
Inclusion Criteria: 1. In- or outpatients, at least 18 years of age up until 65. 2. Being willing and able to provide written informed consent. Having a legal guardian to cosign is allowed. Informed consent will be signed at visit 1, before any study procedure. 3. Female subjects of child bearing potential must use effective contraception during the trial as per the requirements of the applicable SmPCs and should have a negative pregnancy test at visit 1 or 2 (before randomisation). 4. Meeting diagnostic criteria for a primary diagnosis of major depressive disorder (without psychotic features), according to DSM-5. The primary diagnosis will be confirmed by the Mini International Neuropsychiatric Interview (MINI v7.0.2). 5. Subject experiences a treatment failure due to lack of efficacy in the current episode, as confirmed by a CGI-I ≥3; perferably, this treatment is a first-line pharmacotherapeutic agent for the primary DSM-5 diagnosis, and was prescribed for at least 4 weeks within an effective dose range as specified in the Summary of Product Characteristics (SmPCs). 6. Subject and clinician intend to change pharmacotherapeutic treatment. However, other lines of treatment are allowed as well. 7. A minimum symptom severity threshold needs to be present (moderate level; see below) and subject needs to experience functional impairment. * The minimum symptom severity threshold is a score of ≥20 on the Montgomery Åsberg Depression Rating Scale (MADRS) * Functional impairment is defined as a score of 5 or higher on any of the three scales of the Sheehan Disability Scale (SDS). Exclusion criteria: 1. Being pregnant or breastfeeding. 2. Subject has used (es)ketamine previously for the treatment of depressive symptoms. 3. Subject has a known intolerance to (es)ketamine or to all TAU medication. 4. Meeting any of the contraindications for (es)ketamine, or to all TAU medication options, as specified within the applicable SmPC, supported by clinically significant abnormal values on local laboratory tests, electrocardiogram (ECG) or physical examinations. 5. Subject has participated in another clinical trial in which the subject received an experimental or investigational drug or agent within 30 days before visit 1. 6. Subject experiences any other significant disease or disorder which, in the opinion of the investigator, may either put the subjects at risk because of participation in the trial, or may influence the result of the trial, or the subject's ability to participate in the trial. 7. Subjects with active suicidal ideation with some intent to act, without specific plan ("Yes" to question 4 of the Columbia-Suicide Severity Rating Scale (C-SSRS)) or active suicidal ideation with specific plan and intent ("Yes" to question 5 of the C-SSRS), followed by an assessment by the treating clinician who determines it is not safe for the subject to participate in the study 8. Subject meets criteria for current substance use disorder, as confirmed by the Mini International Neuropsychiatric Interview (MINI v7.0.2). Nicotine dependency is allowed, as well as mild and moderate alcohol and/or cannabis use disorder (as defined by MINI v7.0.2). Severe alcohol and/or cannabis use disorder are not allowed. 9. Subjects have not been committed to an institution by virtue of an order issued either by the judicial or the administrative authorities. 10. Subjects dependent on the sponsor, investigator or trial site must be excluded from participation in advance.
Conditions Major Depressive Disorder, Bipolar Disor...
Phase Not Applicable
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this research is to measure brain activity in individuals with mood disorders and memory problems using a simple, safe, and noninvasive method called functional near-infrared spectroscopy (fNIRS). By comparing brain activity across different groups and relating it to symptom severity, this study aims to improve our understanding of how these conditions affect the brain.

Design

Study type: Observational Observational model: Case Control Time perspective: Cross Sectional

Interventions / Regimen

  • Other: Observational assessment using functional near-infrared spectroscopy (fNIRS), a noninvasive, portable brain imaging tool that measures changes in brain blood flow and oxygen levels. — Functional near-infrared spectroscopy (fNIRS) transcutaneously measures changes in oxyhemoglobin in the prefrontal cortex using light detection. It is designed to measure variations in cerebral hemodynamics on a real-time basis by radiating a near light beam, at two wavelengths of 780nm and 850nm of laser, into the cerebral cortex. Participants will undergo a one-time functional near-infrared spectroscopy (fNIRS) procedure to measure cerebral hemodynamic patterns. * Resting-State Measurement: 5-10 min resting-state scans. * Task-Based Measurement: Participants will be shown an instruction video. Participants will complete a Verbal Fluency Task (VFT) during the fNIRS scan (15-20 min). * During the fNIRS scan, optional basic vital signs will be measured using respiratory belts, photoplethysmography (PPG), and electrocardiogram (ECG). * Each participant will complete 3 sets of resting-state and task-based measurements. Total estimated time for fNIRS assessment: 45-60 min.

Primary Outcomes

  • Changes in oxyhemoglobin (Baseline, 60 minutes)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-03-26
Completion: 2028-03-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: Not specified
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Mayo Clinic
Principal Investigators:
  • Maria I. Lapid, M.D. (PRINCIPAL_INVESTIGATOR) - Mayo Clinic
  • Paul H. Min, Ph.D. (PRINCIPAL_INVESTIGATOR) - Mayo Clinic
Contact Information
Study Contact:
Sarah M. Williams
507-422-2972
Williams.Sarah2@mayo.edu
Sarah M. Williams
507-422-2972
Mayo Clinic
Maria I. Lapid, M.D.
Mayo Clinic
Interventions
  • Other: Observational assessment using functional near-infrared spectroscopy (fNIRS), a noninvasive, portable brain imaging tool that measures changes in brain blood flow and oxygen levels. — Functional near-infrared spectroscopy (fNIRS) transcutaneously measures changes in oxyhemoglobin in the prefrontal cortex using light detection. It is designed to measure variations in cerebral hemodynamics on a real-time basis by radiating a near light beam, at two wavelengths of 780nm and 850nm of laser, into the cerebral cortex. Participants will undergo a one-time functional near-infrared spectroscopy (fNIRS) procedure to measure cerebral hemodynamic patterns. * Resting-State Measurement: 5-10 min resting-state scans. * Task-Based Measurement: Participants will be shown an instruction video. Participants will complete a Verbal Fluency Task (VFT) during the fNIRS scan (15-20 min). * During the fNIRS scan, optional basic vital signs will be measured using respiratory belts, photoplethysmography (PPG), and electrocardiogram (ECG). * Each participant will complete 3 sets of resting-state and task-based measurements. Total estimated time for fNIRS assessment: 45-60 min.
Study Locations (1 sites)
Mayo Clinic, Rochester, Minnesota 55905 United States
Eligibility Criteria
Inclusion Criteria General Inclusion Criteria (across all diagnostic groups): * 18 years and older * Ability to provide written informed consent * Adequate cognitive and language abilities to understand and complete study tasks, including clinical assessments and fNIRS procedures * Confirmed clinical diagnosis of major depressive disorder, bipolar disorder, or mild cognitive impairment (MCI) * Stable psychiatric or cognitive condition, without acute episodes requiring immediate intervention Specific Inclusion Criteria (for diagnostic groups): * Healthy control o No past or current psychiatric or cognitive disorder * Major depressive disorder (MDD): * Diagnosis of major depressive disorder, confirmed through clinical evaluation. * No history of bipolar disorder or psychotic symptoms. * Bipolar disorder: o Diagnosis of bipolar disorder I or II, confirmed through clinical evaluation. * Mild Cognitive Impairment (MCI): * Pre-existing clinical diagnosis of mild cognitive impairment, supported by neuropsychological testing and/or MRI, PET scan data. * No history of major psychiatric disorders, such as major depression, bipolar disorder or schizophrenia. Exclusion Criteria General Exclusion Criteria (across all diagnostic groups): * Active primary psychotic or substance use disorders (except nicotine dependence) within the past year * Any severe or unstable medical condition that could interfere with participation or data collection * Any active neurological condition (including seizure disorder, traumatic brain injury, stroke) that could affect cognitive functioning or brain imaging results * Inability to comply with study procedures, including cognitive testing, fNIRS assessment, or other assessments required by the protocol * Pregnant women will be excluded due to potential physiological changes that could affect study outcomes Specific Exclusion Criteria (for diagnostic groups): * Healthy control o Any past or current psychiatric or cognitive disorder * Major depressive disorder (MDD): * Diagnosis of bipolar disorder or schizophrenia. * Brain stimulation therapy within the past 3 months. * Bipolar disorder: o Diagnosis of schizophrenia or schizoaffective disorder. * Mild Cognitive Impairment (MCI): * Diagnosis of dementia. * Significant cognitive impairment preventing understanding or completion of study tasks.
Conditions Malignant Tumor, Anxiety, Depression
Phase Not Applicable
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

This study was a single-center prospective, real-world observational study with plans to enroll all eligible patients. The basic information, anxiety and depression, treatment and prognosis of these patients were collected.

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Interventions / Regimen

  • Other: Hospital Anxiety and Depression Scale — The basic information, anxiety and depression, treatment and prognosis of these patients were collected.

Primary Outcomes

  • Hospital Anxiety Depression Scale (Confirmed in 1 day)
  • Hospital Anxiety Depression Scale (End of the treatment)
  • Hospital Anxiety Depression Scale (The treatment ended 3 months later)
  • Hospital Anxiety Depression Scale (The treatment ended 6 months later)
  • Hospital Anxiety Depression Scale (The treatment ended one year later)
  • Hospital Anxiety Depression Scale (The treatment ended 2 years ago)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-05-20
Completion: 2032-11-30
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Henan Cancer Hospital
Contact Information
Study Contact:
Wang Jiaqiang, Dr
13592413731
wjqwtj@126.com
Tian Zhichao, Dr.
+8618737187831
tianzhichhaoyy@163.com
Department of Bone and Soft Tissue ,Henan Cancer Hospital
Interventions
  • Other: Hospital Anxiety and Depression Scale — The basic information, anxiety and depression, treatment and prognosis of these patients were collected.
Study Locations (1 sites)
Department of Bone and Soft Tissue ,Henan Cancer Hospital, Zhengzhou, Henan 450008 China
Eligibility Criteria
Inclusion Criteria: 1. Men and women of all ages are welcome. 2. Pathological diagnosis of malignant tumor in our hospital. 3. Received at least one hospitalization at this hospital. 4. The expected survival time is greater than 1 year. Exclusion Criteria: 1.There was no pathological report of malignancy.
Conditions Hypertension, Primary Aldosteronism, Hyp...
Phase Not Applicable
Enrollment 80
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

The study aims to provide quantitative facts on the pathophysiological changes in tissue Na+ content during Na+/K+ redistribution disorders in patients with PA in response to standard therapy. The investigators hypothesize that patients with primary aldosteronism have excessive Na+ storage in the muscle, which can now be quantified non-invasively using 23NaMRI. In analogy to the role of HbA1c as a metabolic long-term marker in diabetes, the quantifiable changes in muscle Na+ content may deliver the data evidence necessary to justify and conduct randomized diagnostic endpoint outcome trials in the future, with the ultimate aim to improve PA detection rate and treatment.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: 23NaMRI Scan — 23NaMRI, a non-invasive detection and quantification of hidden tissue Na+ stores in humans.
  • Dietary Supplement: Potassium Chloride (KCl) — K+ supplementation intervention is given participants as part of their standard care. In this trial the K+ supplementation dosage is standardized and adjusted based on blood K+ level

Primary Outcomes

  • Patients with primary aldosteronism have a 10-20% higher muscle Na+ content compared to healthy controls (Baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-12-27
Completion: 2026-08-31
Eligibility
Age: 21 Years – 70 Years
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Jens Titze
Collaborators: Changi General Hospital, Singapore General Hospital, Sengkang General Hospital
Principal Investigators:
  • Jens Titze, MD (PRINCIPAL_INVESTIGATOR) - Duke-NUS Graduate Medical School
Contact Information
Study Contact:
Tzy Tiing Lim
+65 6516 7666
tzytiing.lim@duke-nus.edu.sg
Marton Adriana, MD
adriana.marton@duke-nus.edu.sg
Joanna Teo
Teo_Hwee_Ling@cgh.com.sg
Singapore General Hospital
Interventions
  • Diagnostic Test: 23NaMRI Scan — 23NaMRI, a non-invasive detection and quantification of hidden tissue Na+ stores in humans.
  • Dietary Supplement: Potassium Chloride (KCl) — K+ supplementation intervention is given participants as part of their standard care. In this trial the K+ supplementation dosage is standardized and adjusted based on blood K+ level
Study Locations (4 sites)
Singapore General Hospital, Singapore, 169608 Singapore
Duke NUS Medical School, Singapore, 169857 Singapore
Changi General Hospital, Singapore, 529889 Singapore
Sengkang General Hospital, Singapore, 544886 Singapore
Eligibility Criteria
Inclusion Criteria: 1. Age 21-70 years, with arterial hypertension or suspected to have primary aldosteronism based on Endocrine Society Guidelines. 2. Male and female patients older than 21 years. 3. Willingness to participate and ability to provide informed consent. Exclusion Criteria: 1. Patients with exclusion criteria for the MRI, such as: * implanted devices (surgical clips, heart pacemakers or defibrillators, cochlear implants) * iron-based tattoos * any other pieces of metal or devices that are not MR-Safe anywhere in the body * patients who exhibit noticeable anxiety and/or claustrophobia into the MRI scanner * pregnancy 2. Diagnosis of heart failure NYHA classes III and IV 3. Impaired renal function with eGFR\<30 ml/min or proteinuria \> 1 g/24h 4. Liver disease with cirrhosis (Child-Pugh class C) or hypoalbuminemia 5. Muscular dystrophies 6. Patients with active cancer or severe comorbid conditions likely to compromise survival or study participation 7. Unwillingness or other inability to cooperate
Conditions Pulmonary Hypertension
Phase Not Applicable
Enrollment 70
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

This prospective multicenter longitudinal study aims to investigate the prevalence, pathogenesis, and prognosis of pulmonary hypertension in patients with end-stage renal disease undergoing chronic hemodialysis. The research seeks to identify specific clinical factors and biomarkers like angiopoietin-2 that contribute to the development of this condition, while evaluating the prognostic value of right ventricular function measured via TAPSE. Participants undergo a standardized screening echocardiogram the day after their intermediate dialysis session to determine the probability of pulmonary hypertension. Those identified as high-risk receive further diagnostic confirmation through right heart catheterization, respiratory function tests, and lung scans to clarify the underlying etiology. The protocol also evaluates the hemodynamic impact of high-flow arteriovenous fistulas and volume overload on pulmonary pressures. Clinical follow-up is conducted at baseline and subsequently at 6, 12, and 24 months to monitor patient outcomes and standardize therapeutic management according to established European guidelines.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Prevalence of pulmonary hypertension and its subtypes in patients undergoing chronic hemodialysis (Baseline (enrollment))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2018-11-10
Completion: 2026-09
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: Not specified
Enrollment: 70 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia
Contact Information
Study Contact:
Teresa Rampino, MD
0382504504
t.rampino@smatteo.pv.it
Fondazione IRCCS Policlinico San Matteo di Pavia
Interventions
N/A
Study Locations (1 sites)
Fondazione IRCCS Policlinico San Matteo di Pavia, Pavia, Lombardy 27100 Italy
Eligibility Criteria
Inclusion Criteria: * Patients aged between 18 and 75 years * Patients on stable extracorporeal hemodialysis for at least 6 months * Dialysis frequency of two or three times per week * Ability to provide written informed consent Exclusion Criteria: * WHO functional class IV * Presence of valvular or congenital heart disease * Acute infections within the month preceding the cardiological evaluation

Swiss Postpartum Hypertension Cohort

NCT04690660
Recruiting
Conditions Postpartum Hypertension (PPHT)
Phase Not Applicable
Enrollment 480
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

This open label, prospective observational, single-center registry is to study short-, intermediate-and long-term course of postpartum hypertension and predictors/risk factors associated with long term cardiovascular and renal risk. Current disease management strategies will be evaluated.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Data collection for parameters of organ damage (cardiac and renal blood markers) — Blood results will be taken out of next routine venipuncture. Routinely collected standard parameters are a blood count, chemistry panel including renal parameters and electrolytes, lipid profile and a HbA1c as well as albumin/creatinine and protein/creatinine ratio in urine.
  • Other: Data collection for blood pressure (BP) — Clinic blood pressure and 24hour BP Measurements
  • Other: Home-based blood pressure management (substudy) — Subjects participating in home-based blood pressure management via telemonitoring will receive a free HekaHealth application (App) for the structured assessment of HBPM.
  • Other: Biomarker Profiles (substudy) — Substudy where possible cardiac, renal and pregnancy related biomarkers will be additionally analyzed. The following biomarkers will be analyzed: N terminal (NT)-proBNP, Troponin, elevated mid-regional pro-atrial natriuretic peptide (ANP), elevated mid-regional pro adrenomedullin (ADM), soluble fms-like tyrosine kinase (sFlt-1), and placenta growth factor (PlGF).
  • Other: Data collection on patient reported outcomes — Data collection on patient reported outcomes (Questionnaire EQ-5D, Questionnaire for App based monitoring )

Primary Outcomes

  • Frequency of persistent hypertension defined by 24 hours BP measurement (through study completion, an average of 5 years)
  • Frequency of persistent hypertension defined by office blood pressure measurement (OBPM, AOBPM) (through study completion, an average of 5 years)
  • Frequency of microalbuminuria (through study completion, an average of 5 years)
  • Frequency of damage to the retina of the eyes (retinopathy) (through study completion, an average of 5 years)
  • Signs of hypertensive heart disease (up to 24 months)
  • Frequency of dyslipidemia (through study completion, an average of 5 years)
  • Frequency of prediabetes/diabetes (through study completion, an average of 5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2020-06-04
Completion: 2030-05
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 480 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital, Basel, Switzerland
Principal Investigators:
  • Thenral Socrates, Dr. med. (PRINCIPAL_INVESTIGATOR) - Medical Outpatient Department and Hypertension Clinic, University Hospital BaselUni
Contact Information
Study Contact:
Thenral Socrates, Dr. med.
+41 61 328 6647
thenral.socrates@usb.ch
Thilo Burkard, Dr. med.
+41 61 328 7738
thilo.burkard@usb.ch
Thenral Socrates, Dr. med.
+41 61 328 6647
thenral.socrates@usb.ch
Medical Outpatient Department and Hypertension Clinic, University Hospital Basel
Interventions
  • Other: Data collection for parameters of organ damage (cardiac and renal blood markers) — Blood results will be taken out of next routine venipuncture. Routinely collected standard parameters are a blood count, chemistry panel including renal parameters and electrolytes, lipid profile and a HbA1c as well as albumin/creatinine and protein/creatinine ratio in urine.
  • Other: Data collection for blood pressure (BP) — Clinic blood pressure and 24hour BP Measurements
  • Other: Home-based blood pressure management (substudy) — Subjects participating in home-based blood pressure management via telemonitoring will receive a free HekaHealth application (App) for the structured assessment of HBPM.
  • Other: Biomarker Profiles (substudy) — Substudy where possible cardiac, renal and pregnancy related biomarkers will be additionally analyzed. The following biomarkers will be analyzed: N terminal (NT)-proBNP, Troponin, elevated mid-regional pro-atrial natriuretic peptide (ANP), elevated mid-regional pro adrenomedullin (ADM), soluble fms-like tyrosine kinase (sFlt-1), and placenta growth factor (PlGF).
  • Other: Data collection on patient reported outcomes — Data collection on patient reported outcomes (Questionnaire EQ-5D, Questionnaire for App based monitoring )
Study Locations (1 sites)
Medical Outpatient Department and Hypertension Clinic, University Hospital Basel, Basel, 4031 Switzerland
Eligibility Criteria
Inclusion Criteria: * all women with hypertensive disorders of pregnancy * postpartum hypertension (blood pressure measurements of systolic ≥140 and/or diastolic ≥ 90mmHg or antihypertensive therapy within the first 14 days after delivery) * women with preexisting hypertension or * women on antihypertensive medication Exclusion Criteria: * delivery \> 14 days * lack of consent to participate in the study, language barriers or lack of general understanding
Conditions Hypertension, Blood Pressure Monitoring,...
Phase Not Applicable
Enrollment 120
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to compare the accuracy, clinical applicability, and usability of different wearable blood pressure monitoring methods integrated in wearable devices, such as smartwatches, in hospitalized patients. The study evaluates novel photoplethysmography (PPG)-based and wrist-oscillometric blood pressure measurement methods against established clinical reference methods (upper-arm cuff measurements on the general ward and invasive arterial blood pressure monitoring (A-line) in the intensive care unit). The main questions the study aims to answer are: * Can novel blood pressure monitoring methods suitable for integration into wearable devices achieve clinically acceptable agreement with established reference measurements? * How does the performance of calibration-dependent wearable devices change over time following calibration? * How does the performance of the investigated methods compare with each other? * How do the investigated methods perform for patients with different pre-existing conditions ? To answer these questions, participants will undergo: * blood pressure measurements using different wearable devices based on PPG and wrist oscillometry * standardized reference blood pressure measurements using an upper-arm cuff (general ward) or an existing invasive arterial line (intensive care unit) * repeated measurements over three consecutive days on the general ward to assess calibration stability and measurement reproducibility,

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Agreement of wearable blood pressure measurement methods with clinical reference measurements (General ward: At each measurement session on study days 1, 2, and 3. ICU: At measurement session on study day 1, approx. 2 hours after device calibration)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-07-20
Completion: 2027-12-31
Eligibility
Age: 21 Years – 85 Years
Sex: ALL
Volunteers: true
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Technische Universität Dresden
Collaborators: Careggi Hospital
Contact Information
Study Contact:
Moritz Herzog, MD
0049 351 458 11501
moritz.herzog@ukdd.de
Interventions
N/A
Study Locations (2 sites)
University Hospital Dresden, Dresden, Saxony 01307 Germany
Careggi University Hospital, Florence, FI 50134 Italy
Eligibility Criteria
Inclusion Criteria: * Blood pressure measurements can be performed on at least one arm, for example no amputation, dialysis shunt, or obstructive dressing * Ability to understand the study information and provide written informed consent * For participants in the intensive care unit: an arterial line placed for clinical reasons Exclusion Criteria: * Wrist circumference exceeds the size range of the investigated wearable devices * Physical or medical conditions preventing placement of the wearable devices, including relevant skin lesions, wounds, severe edema, or patient restraint * Inability to provide written informed consent
Conditions Venous Thromboembolism (VTE), Chronic Th...
Phase Not Applicable
Enrollment 5000
Locations 16 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

PERSEUS is an academic, investigator-initiated, multicenter observational registry of adults with acute pulmonary embolism (PE), promoted by Azienda Ospedaliero-Universitaria Careggi (Florence, Italy). It collects data generated during routine care across the whole course of the disease: pre-hospital care when available, emergency department presentation, the hospital stay (including bedside reassessments in the first 48 hours when performed as part of care) and follow-up up to 5 years. The registry has a retrospective cohort (patients diagnosed from 1 January 2023 until local ethics committee approval, with data taken from medical records) and a prospective cohort (consecutive patients enrolled after approval). Taking part in the registry does not change patient care: all tests and treatments are decided by the treating physicians. The registry aims to describe how acute PE is managed in everyday practice and how often patients die (from any cause and from PE), deteriorate hemodynamically, have recurrent venous thromboembolism or bleeding, and develop long-term complications such as chronic thromboembolic pulmonary hypertension. The database also supports ancillary analyses with separate pre-specified analysis plans, such as the evaluation of existing risk-stratification tools.

Design

Study type: Observational Observational model: Cohort Time perspective: Other

Interventions / Regimen

  • Other: Routine clinical care (no study intervention) — Observational registry. Diagnostic and therapeutic management (laboratory tests, imaging, bedside ultrasound, anticoagulation, reperfusion and hemodynamic support) is entirely at the discretion of the treating physicians, according to routine institutional pathways and international guidelines. The registry only collects data generated in routine care.

Primary Outcomes

  • All-cause mortality at 30 days (30 days after diagnosis)
  • PE-related mortality at 30 days (30 days after diagnosis)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-06-19
Completion: 2032-07
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 5000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Azienda Ospedaliero-Universitaria Careggi
Collaborators: University of Florence, Azienda USL Toscana Centro, Azienda Ospedaliera di Perugia, Cardarelli Hospital, Naples, Italy, Azienda Ospedaliero, Universitaria Pisana, Azienda USL Toscana Nord Ovest, Medical University of Warsaw, Hospital Universitario Ramon y Cajal, A.O.U. Città della Salute e della Scienza - Molinette Hospital
Principal Investigators:
  • Simone Vanni, MD, PhD (PRINCIPAL_INVESTIGATOR) - Azienda Ospedaliero-Universitaria Careggi / University of Florence
  • Matteo Gabriele Monda, MD (STUDY_DIRECTOR) - Azienda Ospedaliero-Universitaria Careggi / University of Florence
Contact Information
Study Contact:
Simone Vanni, MD, PhD
+393666904459
simone.vanni@unifi.it
Matteo Gabriele Monda, MD
+393209433394
matteogabriele.monda@gmail.com
Germana Ruggiano, MD
+39 055 69361
germana.ruggiano@uslcentro.toscana.it
Ospedale Santa Maria Annunziata - Azienda USL Toscana Centro
Interventions
  • Other: Routine clinical care (no study intervention) — Observational registry. Diagnostic and therapeutic management (laboratory tests, imaging, bedside ultrasound, anticoagulation, reperfusion and hemodynamic support) is entirely at the discretion of the treating physicians, according to routine institutional pathways and international guidelines. The registry only collects data generated in routine care.
Study Locations (16 sites)
Ospedale Santa Maria Annunziata - Azienda USL Toscana Centro, Bagno a Ripoli, Tuscany 50012 Italy
Nuovo Ospedale del Mugello - Azienda USL Toscana Centro, Borgo San Lorenzo, Tuscany 50032 Italy
Ospedale San Giuseppe - Azienda USL Toscana Centro, Empoli, Tuscany 50053 Italy
Ospedale Santa Maria Nuova - Azienda USL Toscana Centro, Florence, Tuscany 50122 Italy
Azienda Ospedaliero-Universitaria Careggi, Florence, Tuscany 50134 Italy
Ospedale San Giovanni di Dio (Torregalli) - Azienda USL Toscana Centro, Florence, Tuscany 50143 Italy
Ospedale Santi Cosma e Damiano - Azienda USL Toscana Centro, Pescia, Tuscany 51017 Italy
Ospedale San Jacopo - Azienda USL Toscana Centro, Pistoia, Tuscany 51100 Italy
Ospedale Santo Stefano - Azienda USL Toscana Centro, Prato, Tuscany 59100 Italy
Ospedale Versilia - Azienda USL Toscana Nord Ovest, Lido di Camaiore, Italy
Eligibility Criteria
Inclusion Criteria: * Age 18 years or older at the time of presentation. * Objectively confirmed diagnosis of acute pulmonary embolism (PE), with or without concomitant deep vein thrombosis (DVT) of the lower or upper extremities, confirmed by at least one of the following methods: * Computed tomography pulmonary angiography (CTPA) demonstrating intraluminal filling defects in the pulmonary arterial tree; * Ventilation/perfusion (V/Q) lung scintigraphy demonstrating high-probability mismatch; * Conventional catheter-directed pulmonary angiography; * In hemodynamically unstable patients (obstructive shock or cardiac arrest) in whom definitive imaging is not feasible: bedside point-of-care ultrasound showing clear signs of right ventricular overload together with proximal deep vein thrombosis, or mobile right heart thrombi. * For the retrospective cohort: availability of medical records documenting clinical presentation and index diagnostic work-up at baseline (T0). The absence of serial reassessment timepoints (T1-T4) does not constitute an exclusion criterion. * Written informed consent obtained from the patient or legal surrogate, or waiver/exception under Article 110-bis of the Italian Privacy Code (and applicable institutional ethical clearance) for deceased or untraceable patients. Exclusion Criteria: * Current active enrollment in an interventional experimental drug trial (blinded randomized clinical trial) where active drug allocation or protocol-mandated therapeutic regimen is unknown.
Conditions Angle-Closure Glaucoma
Phase Not Applicable
Enrollment 825
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

The Beijing angle closure progression study (BAPS) aims to explore the 5-year incidence of PACS progressing to PAC or PACG and to determine the possible risk factors of disease progression, which may provide the evidence for choosing the accurate strategies in the management of PACS.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • the progression rate 1 (6 months)
  • the progression rate 2 (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-08-04
Completion: 2030-12-31
Eligibility
Age: 40 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 825 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Peking University People's Hospital
Contact Information
Study Contact:
Huijuan Wu, M.D. Ph.D.
8613811293109
dr_wuhuijuan@126.com
Huijuan Wu
8613811293109
dr_wuhuijuan@126.com
Peking University People's Hospital
Interventions
N/A
Study Locations (1 sites)
Peking University People's Hospital, Beijing, Beeijing 100044 China
Eligibility Criteria
Inclusion Criteria: * "Static" gonioscopy identifying 6 or more clock hours of angle circumference in which the posterior (usually pigmented) trabecular meshwork cannot be seen in both eyes with no peripheral anterior synechiae, and normal intraocular pressure (IOP), optic nerve and visual field. * Able to provide informed consent Exclusion Criteria: * Any evidence of primary angle closure (a narrow angle as defined above, but with PAS and/or IOP \> 21 mmHg) or primary angle closure glaucoma (visual field defect or glaucomatous optic neuropathy). * Previous intraocular surgery or laser treatment, such as cataract surgery, laser trabeculoplasty, trabeculectomy, laser peripheral iridectomy, and laser iridoplasty * Sign of prior acute attack, such as glaucomatous fleck, keratic precipitates, or iris atrophy. * Anterior segment structural abnormalities shown by examination, such as iris or ciliary body tumor. * Severe health problems precluding follow-up such as end-stage heart disease, kidney disease, or lung disease, or terminal cancer. * Severe eye diseases, such as cataract, macular disease, and retinal detachment.
Conditions Pulmonary Hypertension
Phase NA
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn the effectiveness of remote home-based exercise rehabilitation using mobile Internet technology for patients with pulmonary hypertension,especically providing early and mid-term results of its effectiveness. The main questions it aims to answer are: Dose tele-rehabilitation training improves prognostic function and quality of life in patients with pulmonary hypertension? Researchers will compare tele-rehabilitation training group to a control group (receive health propaganda and education, and then follow their daily routine after discharge from the hospital) to see if tele-rehabilitation training works to improve prognosis. Participants will: During their stay in the hospital, the patients of tele-rehabilitation training group were accompanied by a rehabilitation trainer and a psychotherapist for a complete cycle of (7 days ± 3 days 1 week/times) standardized training. The scheme of rehabilitation is impedance training. A specialized professional team including cardiologists, rehabilitation trainers, psychotherapists and radiologists were involved. After discharge from the hospital, patients in the rehabilitation group underwent 3-5 weekly daily training sessions and intensive supervision and management by the online community at least once a week. Visit the clinic at the 3rd month of the study. Extended follow-up up to 6 months may be considered if patients are cooperative and could complete the training program in the first 3 months.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: tele-rehabilitation training — During their stay in the hospital, the patients were accompanied by a rehabilitation trainer and a psychotherapist for a complete cycle of (7 days ± 3 days 1 week/times) standardized training. After discharge from the hospital, patients in the rehabilitation group underwent 3-5 weekly daily (a total of 3 months)training sessions and intensive supervision and management by the online community at least once a week. All patients' routines were monitored by telemetry and data, photographs and video recordings were collected by a specialized agency. The scheme of rehabilitation is impedance training. A specialized professional team including cardiologists, rehabilitation trainers, psychotherapists and radiologists were involved.
  • Behavioral: health propaganda and education — During their stay in the hospital, participants of the control group received health propaganda and education (7 days ± 3 days 1 week/times). After discharge from the hospital, the control group followed their daily routine.

Primary Outcomes

  • changes in 6MWD after 3 months (3th month after enrollment)
  • changes in muscle mass after 3 months (3th month after enrollment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-04-22
Completion: 2026-05-01
Eligibility
Age: 18 Years – 60 Years
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: China-Japan Friendship Hospital
Contact Information
Study Contact:
Xiaoming Zhou, MD
+86 88396992
zhouxmcmu@163.com
Xiaoming Zhou, MD
+86 88396992
zhouxmcmu@163.com
Fuwai Hospital
Xiaoming Zhou, MD
Fuwai Hospital
Interventions
  • Behavioral: tele-rehabilitation training — During their stay in the hospital, the patients were accompanied by a rehabilitation trainer and a psychotherapist for a complete cycle of (7 days ± 3 days 1 week/times) standardized training. After discharge from the hospital, patients in the rehabilitation group underwent 3-5 weekly daily (a total of 3 months)training sessions and intensive supervision and management by the online community at least once a week. All patients' routines were monitored by telemetry and data, photographs and video recordings were collected by a specialized agency. The scheme of rehabilitation is impedance training. A specialized professional team including cardiologists, rehabilitation trainers, psychotherapists and radiologists were involved.
  • Behavioral: health propaganda and education — During their stay in the hospital, participants of the control group received health propaganda and education (7 days ± 3 days 1 week/times). After discharge from the hospital, the control group followed their daily routine.
Study Locations (1 sites)
Fuwai Hospital, Beijing, Beijing Municipality 100037 China
Eligibility Criteria
Inclusion Criteria: * 1\. age 18- 60 years old; * 2\. PH were defined as: mPAP \> 20 mmHg, PAWP ≦ 15 mmHg and PVR \> 2 WU measured by right heart catheterization at sea level at rest; * 3\. Arterial Pulmonary Hypertension (PAH), pulmonary hypertension associated with lung diseaseor and Chronic Thromboembolic Pulmonary Hypertension (CTEPH) according to the WHO PH Classification; * 4\. no syncope or syncopal aura during walking or recovery. * 5\. no serious arrhythmia caused by rest or exercise such as ventricular tachycardia, ventricular fibrillation, Class III atrioventricular block, etc. * 6\. stable medication and medication regimen for at least 3 months prior to randomization and no organized exercise training of any kind for at least 3 months prior to screening * 7\. be proficient in the use of smartphones and monitoring devices; * 8\. sign an informed consent form. Exclusion Criteria: * 1\. combined with VTE. * 2\. acute pulmonary embolism. * 3\. low-intensity exercise (\<3METs) or angina pectoris symptoms/signs during the recovery period. * 4\. hemodynamic abnormality during exercise (especially systolic blood pressure doesn't rise or fall or arrhythmia occurs when the exercise load is increased). * 5\. severe psycho-cognitive disorders. * 6\. couldent do exercise due to the neurological or musculoskeletal dysfunction. * 7\. patients with CTEPH who are scheduled to undergo percutaneous pulmonary artery balloon dilatation or pulmonary artery endarterectomy within 6 months. * 8\. patients with a combination of other consumptive underlying diseases, such as malignant tumors, pulmonary tuberculosis, hyperthyroidism, severe depression, etc. * 9\. pregnancy. * 10\. refused to sign the informed consent form.
Conditions Portal Hypertension
Phase Not Applicable
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

A minimally invasive procedure to directly assess portal pressure gradient under endoscopic ultrasound guidance (EUS-PPG) has become available and initial data have proved the technique to be safe. Aims of our proposal are: (i) to assess performance of EUS-PPG as compared to HVPG in evaluating hemodynamic response to non selective betablockers (NSBBs) in a large cohort of patients with CSPH;(ii) identification of markers of hemodynamic response(iii) identification of factors potentially affecting the accuracy of PPG measurement.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Device: EUS PPG measurement — Direct EUS PPG measurement

Primary Outcomes

  • Measurement of the portal pressure gradient though endoscopic ultrasound (EUS) and hepatic venous pressure gradient (HVPG) to evaluate the hemodynamic response to non-selective beta blockers (NSBBs) (24 months)
  • HVPG Measurement Before and After NSBB Titration in Portal Hypertension (24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-09-11
Completion: 2026-04-01
Eligibility
Age: 18 Years – 99 Years
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Principal Investigators:
  • Francesco Santopaolo, MD (PRINCIPAL_INVESTIGATOR) - Fondazione Policlinico A. Gemelli IRCCS, Rome
Contact Information
Study Contact:
Francesco Santopaolo, MD
+393492754288
francesco.santopaolo@policlinicogemelli.it
Elisabetta Creta, SC
elisabetta.creta@policlinicogemelli.it
Francesco Santopaolo, MD
+393492754288
francesco.santopaolo@policlinicogemelli.it
Policlinico Gemelli IRCCS
Interventions
  • Device: EUS PPG measurement — Direct EUS PPG measurement
Study Locations (1 sites)
Policlinico Gemelli IRCCS, Roma, 00168 Italy
Eligibility Criteria
Inclusion Criteria: * Patients with newly diagnosed esophago-gastric varices or with high suspicion of CSPH at non-invasive tests (porto- systemic collaterals at imaging, platelet count \<150.000 x mm3, spleen size \>13 cm in the largest axis, alteration of elastography parameters of the liver or spleen) * naïve to treatment with NSBBs, Exclusion Criteria: * Child Pugh \>A6 * Hepatocellular carcinoma * Portal vein thrombosis
Conditions Hypertension, Medication Adherence, Bloo...
Phase NA
Enrollment 500
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

Despite evidence of preventing cardiovascular disease (CVD) risk through lifestyle changes, many patients with hypertension (HTN) do not comply with this and suffer from CVD and other complications. A previous study using a structured lifestyle intervention program has reported a 14% decrease in the 10-year risk of developing CVD at one year among hypertensive and diabetes patients. Low and Middle-Income countries (LMICs) struggle with a shortage of health workers to deliver such interventions. In this context, mobile phones can contribute to bridging this gap by incorporating them into the health system for health intervention delivery. There is a need to develop contextual mHealth intervention adapted to local needs and culture and test its effectiveness in LMIC settings like Nepal. Our previous small-scale pilot mHealth (text messages) study reported promising evidence in reducing blood pressure among hypertensive patients in the intervention arm \[adjusted reduction in systolic blood pressure (BP) -6.50 (95% CI, -12.6; -0.33) and diastolic BP -4.60 (95% CI, -8.16; -1.04)\], with a greater proportion achieving target BP (70% vs 48% in the control arm, p = 0.006)\] and improving treatment compliance (p \< 0.001) in Nepal. This finding supports the expansion to a large-scale trial of a structured mHealth intervention to see its long-term effectiveness and sustainability for patients with HTN to improve BP control and reduce CVD risk. Hence, this study aims to assess the effectiveness of a behavioural intervention through mHealth (telephone/mobile phone calls and text messages) informed by the RE-AIM framework for improving blood pressure control among patients with hypertension in a hospital (Manamohan Cardiothoracic Vascular and Transplant Center) of Kathmandu, Nepal.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: Phone call and text Messages — The intervention consists of recommended lifestyle counselling (on a healthy diet, physical activity, smoking, alcohol intake, medication adherence and continuity of care). This counselling will be provided through the research nurse at baseline and for six months (tentative plan phone call once a month; frequency and duration will be finalized based on formative study) by calling on participants' given mobile numbers. In addition, text message reminders on the same topics will be delivered regularly (2-3 times a week) for six months. The counselling and message will focus on three domains of COM-B; capabilities needed, opportunities and practical tools, and motivation strategies informed by behaviour change techniques.

Primary Outcomes

  • Systolic Blood Pressure (baseline, 6 and 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-11-02
Completion: 2027-12-31
Eligibility
Age: 18 Years – 70 Years
Sex: ALL
Volunteers: true
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Central Department of Public Health
Collaborators: Harvard School of Public Health (HSPH), Apara Innovations Pvt. Ltd
Principal Investigators:
  • Buna Bhandari Bhattarai, PhD (PRINCIPAL_INVESTIGATOR) - Indiana University
Contact Information
Study Contact:
Buna Bhandari, PhD
8508156644
buna.bhandari@gmail.com
Rabina Dhakal, MPH
977 9841075217
dhakalrabina@gmail.com
Rikesh Tamrakar, DM
Sahid Gangalal National Heart Center
Interventions
  • Behavioral: Phone call and text Messages — The intervention consists of recommended lifestyle counselling (on a healthy diet, physical activity, smoking, alcohol intake, medication adherence and continuity of care). This counselling will be provided through the research nurse at baseline and for six months (tentative plan phone call once a month; frequency and duration will be finalized based on formative study) by calling on participants' given mobile numbers. In addition, text message reminders on the same topics will be delivered regularly (2-3 times a week) for six months. The counselling and message will focus on three domains of COM-B; capabilities needed, opportunities and practical tools, and motivation strategies informed by behaviour change techniques.
Study Locations (2 sites)
Sahid Gangalal National Heart Center, Kathmandu, Bagmati Nepal
Apara Innovations Pvt Ltd, Kathmandu, Pradesh 3 (Bagmati) 40660 Nepal
Eligibility Criteria
Inclusion Criteria: * Clinical diagnosis of hypertension * Currently receiving/prescribed blood pressure-lowering medication for more than three months * With uncontrolled blood pressure (\>130/80mm of Hg) * Should have access to a mobile phone * Able to read text messages ( by themselves/with the help of family) Exclusion Criteria: * Diagnosed with myocardial infarction, stroke, and kidney failure * Severe mental illness, cognitive impairment * Pregnant women or in the postpartum period